Selecting one or more of the options below will update the content below.

Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    Ontario

    What is this Study about?

    Participants will receive drug treatment via IV in clinic on Day 1 and every 4 weeks thereafter.

    Eligibility Criteria

    • Age 50-85 years old
    • Diagnosis of early AD 

    Recruitment End Date

  • Clinical Trial
    Ontario

    What is this Study about?

    Multi-center, Double-Blind, Placebo-Controlled Phase 1/2 Trial to Assess the Safety and Tolerability of WVE-3972-01 Administered Intrathecally to Patients with Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD).

    Eligibility Criteria

    • 18 Years to 80 Years
    • Participants must have a documented mutation (GGGGCC [G4C2] repeat expansion) in the first intronic region of the C9orf72 gene and be diagnosed with ALS or FTD.
    • Have a designated study partner

    Recruitment End Date

  • Clinical Trial
    Ontario

    What is this Study about?

    A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period.

    Eligibility Criteria

    • 50 Years to 80 Years
    • Diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD
    • Have a designated study partner

    Recruitment End Date

  • Clinical Trial
    British Columbia, Nova Scotia, Ontario, Quebec

    What is this Study about?

    A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE).

    Eligibility Criteria

    • 55 Years to 85 Years 
    • MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type
    • Have a designated study partner

    Recruitment End Date

  • Clinical Trial
    British Columbia, Nova Scotia, Ontario, Quebec

    What is this Study about?

    A Phase 3 randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)

    Eligibility Criteria

    • 55 Years to 85 Years 
    • MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type
    • Have a designated study partner

    Recruitment End Date

  • Clinical Trial
    Ontario

    What is this Study about?

    A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease

    Eligibility Criteria

    • 55 Years to 80 Years
    • Early Alzheimer's disease (AD)
    • Have a designated study partner

    Recruitment End Date

  • Observational Study
    Ontario

    What is this Study about?

    The Health in Aging, Neurodegenerative Diseases and Dementias in Ontario (HANDDS-ONT) Study is an observational study that takes place in the comfort of participant’s home, with no study visits occurring in a clinic. The study is recruiting people living with and without a neurodegenerative disease (see below) or the effects of stroke. Studying both groups will help ONDRI researchers to:

    • understand how the diseases affect different people
    • discover ways to potentially detect diseases earlier
    • explore ways to help people manage their daily health related behaviours

    All data collected will be anonymized and will be stored securely by the Ontario Brain Institute.

    Eligibility Criteria

    • At least 18 years of age
    • A resident of Ontario, and
    • Must fall under one of the below categories:
      • A) Living with a neurodegenerative disease such as:
        • Alzheimer’s Disease/Mild Cognitive Impairment
        • Parkinson’s Disease
        • Amyotrophic Lateral Sclerosis
        • Frontotemporal Dementia
      • B) Living with the effects of a stroke  
        Or
      • C) Living independently with no diagnosis of a neurodegenerative disease

    Recruitment End Date

  • Observational Study
    Canada-Wide

    What is this Study about?

    The Rare Dementia Support Impact Study is a cross-national 5-year collaboration between Nipissing University, Canada; University College London (UCL), England; and Bangor University, Wales, and the world’s largest study on rare dementia support. More than 5% of people living with dementia have a rare or young onset type, which is not well understood. 

    Eligibility Criteria

    • Person living with a rare form of dementia or young onset dementia
    • Caregiver for someone with rare or young onset dementia
    • 18 years of age or older
    • Reside in Canada

    Recruitment End Date

  • Clinical Trial
    Ontario

    What is this Study about?

    This is a phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study that will assess efficacy and safety of AL002 administered intravenously (IV) in participants with Early Alzheimer's Disease.

    Eligibility Criteria

    • 50-85 years old
    • Diagnosis of early Alzheimer's Disease

    Recruitment End Date